Early Adcetris OK no surprise to SGEN after taking US FDA's advice

The US FDA has been on a roll this month with approving cancer drugs ahead of schedule, with the latest being Seattle Genetics' Adcetris (brentuximab vedotin), the first therapy in 34 years available to treat patients with Hodgkin’s lymphoma (HL) – coming 11 days early, triggering a 14.2% jump in the Bothell, Washington-based biotech's stock on 19 August.